Brief: Bone Therapeutics H1 Operating Income Down At 1.04 Million Euros

Biosenic SA

26/08/2020 06:23

Aug 26 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * REPORTS HALF YEAR 2020 RESULTS
    * RECRUITMENT OF JTA-004 PHASE III STUDY IN KNEE
OSTEOARTHRITIS ON
TRACK TO BE COMPLETED BY YEAR-END
    * PHASE IIB TRIAL WITH ALLOB IN TIBIAL FRACTURES APPROVED IN
MOST
COUNTRIES READY TO START IN H2 2020
    * A TOTAL AMOUNT OF EUR 15.0 MILLION COMMITTED GROSS
PROCEEDS
RAISED IN TWO SUCCESSFUL FUNDING OPERATIONS TO SUPPORT CLINICAL
PROGRESS
    * BROADENING PRODUCT PORTFOLIO FROM ORTHOPEDICS INTO
INFLAMMATORY
CONDITIONS, LEVERAGING BONE THERAPEUTICS' ALLOGENEIC MSC
PLATFORM
    * DURING FIRST SIX MONTHS OF 2020, TOTAL OPERATING INCOME
AMOUNTED
TO EUR 1.04 MILLION, A SLIGHT DECREASE COMPARED TO SAME PERIOD
IN 2019
    * H1 2020 OPERATING LOSS FOR PERIOD AMOUNTED TO EUR 9.10
MILLION,
COMPARED TO EUR 5.44 MILLION IN H1 2019
    * COMPANY ENDED FIRST SIX MONTHS OF 2020 WITH EUR 10.04
MILLION IN
CASH AND CASH EQUIVALENTS
    * EXPECTS TO INITIATE CLINICAL TRIAL ACTIVITIES AND PATIENT
RECRUITMENTS FOR ALLOB PHASE IIB STUDY IN PATIENTS WITH
DIFFICULT TIBIAL FRACTURES IN EUROPEAN CLINICAL CENTERS IN H2
    * CASH USED FOR FULL YEAR 2020 IS ANTICIPATED TO AMOUNT TO
EUR
15.00-16.00 MLN
    * IN NOVEMBER, PLANS TO INITIATE FIRST DISCUSSIONS WITH US
FDA IN
PREPARATION FOR NEXT STEPS IN CLINICAL DEVELOPMENT OF JTA-004 IN
US
    * IN H2, EXPECTS TO REPORT RESULTS FROM 2-YEAR FOLLOW-UP
PERIOD OF
PHASE IIA STUDY WITH ALLOB IN PATIENTS UNDERGOING SPINAL FUSION
PROCEDURE
    * ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT ITS
BUSINESS
OBJECTIVES INTO Q2 2021

Source text for Eikon:  ID:nGNE8c7Lp6 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))